Cognition Therapeutics, Inc. Segment Reporting Other Item Amount
Cognition Therapeutics, Inc. (CGTX) reported Segment Reporting Other Item Amount of -$906.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-03-26
- Cognition Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was -$329.00K, a 316.45% decline year-over-year.
- Cognition Therapeutics, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was -$230.00K.
- Cognition Therapeutics, Inc. segment reporting other item amount for the quarter ending 2024-12-31 was $152.00K.
- Cognition Therapeutics, Inc. segment reporting other item amount for the quarter ending 2024-09-30 was -$233.00K.
- Cognition Therapeutics, Inc. segment reporting other item amount for fiscal 2025 was -$906.00K.
- Cognition Therapeutics, Inc. segment reporting other item amount for fiscal 2024 was -$446.00K.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$329.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$559.00K derived: sum of 2 quarters · filed 2026-03-26 | -$906.00K 10-K · filed 2026-03-26 | |
| 2025-09-30 | -$230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$577.00K 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | -$347.00K 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$81.00K derived: sum of 2 quarters · filed 2026-03-26 | -$446.00K 10-K · filed 2026-03-26 | |
| 2024-09-30 | -$233.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$598.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$365.00K 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |